IVRS
IVRS AB is a Sweden-based preclinical research service provider focused on in vivo models and imaging to support early drug development. Services described on the site include in vivo imaging modalities (bioluminescence and whole-body 3D imaging), development and use of patient-derived xenograft (PDX) and allograft orthotopic models, and end-to-end execution of preclinical studies for drug validation, efficacy, biodistribution and toxicology. The organisation participates in collaborative, grant-funded consortia and lists scientific publications and external marketplace presence.
Industries
Nr. of Employees
small (1-50)
Products
Segment models (PDX-based disease models)
Validated preclinical segment models based on patient-derived xenografts and orthotopic transplantation for indications such as lung, breast, pancreatic cancer and glioblastoma.
Segment models (PDX-based disease models)
Validated preclinical segment models based on patient-derived xenografts and orthotopic transplantation for indications such as lung, breast, pancreatic cancer and glioblastoma.
Services
Preclinical imaging using bioluminescence and whole-body 3D modalities for longitudinal monitoring.
Preclinical study execution to evaluate drug candidates for efficacy and validation in disease-specific models.
Studies to assess distribution of compounds or biologics across tissues using imaging and analytical readouts.
Preclinical toxicology assessments linked to efficacy and biodistribution studies.
Design, validation and provision of disease-specific segment models (PDX and allograft based) for target indications.
Preclinical imaging using bioluminescence and whole-body 3D modalities for longitudinal monitoring.
Preclinical study execution to evaluate drug candidates for efficacy and validation in disease-specific models.
Studies to assess distribution of compounds or biologics across tissues using imaging and analytical readouts.
Preclinical toxicology assessments linked to efficacy and biodistribution studies.
Design, validation and provision of disease-specific segment models (PDX and allograft based) for target indications.
Expertise Areas
- Preclinical in vivo imaging
- PDX and orthotopic tumor model development
- Preclinical drug validation and efficacy testing
- Biodistribution studies
Key Technologies
- In vivo bioluminescence imaging
- Whole-body 3D imaging
- Patient-derived xenografts (PDX)
- Orthotopic transplantation models
News & Updates
Announcement of Eurostars funding for a collaborative project to develop a biologic therapy for Crohn’s disease; highlights partnership and use of in vivo imaging capabilities.
Announcement of €1.36M Eurostars grant and role as partner leveraging in vivo RCC models and whole-body 3D imaging to evaluate a novel inhibitor.
Launch of a new non-small cell lung cancer model using patient-derived xenografts and mouse allografts to replicate clinical features.
Launch of an orthotopic human glioblastoma model using patient-derived xenografts and in vivo bioluminescence imaging.
Named Industry Winner 2024 within Biotechnical Research and Development (national recognition of performance).
Receipt of a Nordic growth certificate indicating business growth.
Announcement of Eurostars funding for a collaborative project to develop a biologic therapy for Crohn’s disease; highlights partnership and use of in vivo imaging capabilities.
Announcement of €1.36M Eurostars grant and role as partner leveraging in vivo RCC models and whole-body 3D imaging to evaluate a novel inhibitor.
Launch of a new non-small cell lung cancer model using patient-derived xenografts and mouse allografts to replicate clinical features.
Launch of an orthotopic human glioblastoma model using patient-derived xenografts and in vivo bioluminescence imaging.
Named Industry Winner 2024 within Biotechnical Research and Development (national recognition of performance).
Receipt of a Nordic growth certificate indicating business growth.